ReviewThe Journal of clinical investigation2003
Ribozyme-mediated revision of RNA and DNA.
Review in The Journal of clinical investigation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Improving Aptamer Affinity and Determining Sequence-Activity Relationships via Motif-SELEX.Journal of the American Chemical Society · 2025Article
- Lariat capping as a tool to manipulate the 5' end of individual yeast mRNA species in vivo.RNA (New York, N.Y.) · 2017Article
- Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.Virology · 2015Article
- Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.Journal of ophthalmology · 2011Article
- Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns.BMC molecular biology · 2010Article
- Targeted gene disruption in Francisella tularensis by group II introns.Methods (San Diego, Calif.) · 2009Article
- Drug targets in hepatitis B virus infection.Infectious disorders drug targets · 2009Review
- Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.Cancer gene therapy · 2009Article
- Targeted inactivation of francisella tularensis genes by group II introns.Applied and environmental microbiology · 2008Article
- In vivo excision of a single targeted nucleotide from an mRNA by a trans excision-splicing ribozyme.RNA (New York, N.Y.) · 2005Article
- Diverse Mechanisms of RNA Recombination.Molecular biology · 2005Article
- Targeted genetic repair: an emerging approach to genetic therapy.The Journal of clinical investigation · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.